Organogenesis Holdings Inc. Class A Common Stock
ORGOOrganogenesis Holdings Inc. Class A (ORGO) is a biotechnology company focused on developing and commercializing advanced regenerative medicine products. It specializes in tissue repair and wound management solutions derived from living cells and biological materials, aiming to improve outcomes in diverse medical fields such as surgical, wound care, and dental applications.
Company News
The global tissue engineering market is projected to grow from USD 15.01 billion in 2026 to USD 27.59 billion by 2031, driven by advancements in regenerative medicine, biomaterials, and stem cell research. Key growth drivers include increasing demand for regenerative therapies, innovations in 3D bioprinting, rising prevalence of chronic diseases,...
Organogenesis Holdings Inc. announced that its randomized controlled trial of PuraPly®AM plus standard of care versus standard of care alone for non-healing diabetic foot ulcers achieved its primary endpoint, demonstrating statistically significant wound closure at 12 weeks (p<0.0477). The company plans to publish results in a peer-reviewed jour...
Pomerantz LLP is investigating potential securities fraud claims on behalf of investors in Vizsla Silver Corp., following a security incident at its Mexico project site on January 29, 2026, where ten individuals were taken and operations were temporarily suspended. The incident triggered a 14.87% stock price decline. The firm is also investigatin...
Pomerantz LLP is investigating potential securities fraud claims against Organogenesis Holdings Inc. following the Centers for Medicare & Medicaid Services' withdrawal of Local Coverage Determinations for skin substitute grafts on December 26, 2025. The withdrawal exposes Organogenesis to increased competition from over 300 market participants. T...
The global wound healing devices market is projected to grow from $29 billion in 2024 to $42 billion by 2032, driven by increasing chronic wounds, technological advancements, and an aging population.
